NCT05794165View on ClinicalTrials.gov

Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

314

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

March 31, 2027

Conditions
Trauma InjuryThromboembolismVenous Thromboembolism
Interventions
DRUG

Thrombate infusion

Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin. The dose will be based on patient weight.

DRUG

Placebo

Normal Saline will be given as one time IV before the 3rd dose of Enoxaparin. The dose will be based on patient weight.

Trial Locations (4)

33136

Jackson Memorial Hospital/University of Miami, Miami

37212

Vanderbilt University Hospital, Nashville

77030

The University of Texas Health Science Center at Houston, Houston

80045

University of Colorado, Aurora

Sponsors

Lead Sponsor

Bryan Cotton
All Listed Sponsors
collaborator

Grifols Shared Services North America, Ind.

UNKNOWN

lead

Bryan Cotton

OTHER

NCT05794165 - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism | Biotech Hunter | Biotech Hunter